Inactivation of wild-type BCR/ABL tyrosine kinase in hematopoietic cells by mild hyperthermia

Leukemia

Volumn 14, Issue 5, 2000, Pages 845-852

  Jain, S K ^a   De Aos, I ^a   Inai, Y ^a   Liu, F ^a   Varticovski, L ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

BCR ABL; Chronic myelogenous leukemia; Temperature sensitivity; Tyrosine kinase; Tyrosine phosphorylation

Indexed keywords

BCR ABL PROTEIN; GENE PRODUCT; GROWTH FACTOR; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE PHOSPHATASE;

ANIMAL CELL; ARTICLE; BINDING SITE; CELL TRANSFORMATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME REGULATION; GENE MUTATION; HEMATOPOIETIC CELL; HYPERTHERMIA; IMMUNOPRECIPITATION; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TEMPERATURE SENSITIVITY;

EID: 0034014152     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401759     Document Type: Article

References (44)

1. Ramakrishnan L, Rosenberg N. abl genes. Biochim Biophys Acta 1989; 989: 209-224.
2. Wiedemann LM, Karhi KK, Shivji MK, Rayter SI, Pegram SM, Dowden G, Bevan D, Will A, Galton DA, Chan LC. The correlation of breakpoint cluster region rearrangement and p210 phl/abl expression with morphological analysis of Ph-negative chronic myeloid leukemia and other myeloproliferative diseases. Blood 1988; 71: 349-355.
3. Daley GQ, Van Etten RK, Baltimore D. Induction of chronic myelogenous leukemia in mice by the p210 bcr/abl gene of the Philadelphia chromosome. Science 1990; 247: 824-830.
4. Daley GQ, Baltimore D. Transformation of an interleukin-3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific p210 bcr/abl protein. Proc Natl Acad Sci USA 1988; 85: 9312-9316.
5. Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990; 247: 1079-1082.
6. Cortez D, Kadlec L, Pendergast AM. Structural and signalling requirements for BCR-ABL mediated transformation and inhibition of apoptosis. Mol Cell Biol 1995; 15: 5531-5541.
7. Hariharan IK, Adams JM, Cory S. BCR-abl oncogene renders myeloid cell line factor independent. Oncogene 1988; 3: 387-399.
8. Nishii K, Kabarowski JHS, Gibbons DL, Griffiths SD, Titley I, Wiedemann LM, Greaves MF. ts BCR-ABL kinase activation confers increased resistance to genotoxic damage via cell cycle block. Oncogene 1996; 13: 2225-2234.
9. Cortez D, Stoica G, Pierce JH, Pendergast AM. The BCR-ABL tyrosine kinase inhibits apoptosis by activating a Ras-dependent signaling pathway. Oncogene 1996; 13: 2589-2594.
10. Cortez D, Reuther G, Pendergast AM. The BCR/abl tyrosine kinase activates mitogenic signaling pathways and stimulates G1-to S phase transition in hematopoietic cells. Oncogene 1997; 15: 2333-2342.
11. Albrecht T, Schwab R, Henkes M, Peschel C, Huber C, Aulitzky WE. Primary proliferating immature myeloid cells from CML patients are not resistant to induction of apoptosis by DNA damage and growth factor withdrawal. Br J Haematol 1996; 95: 501-507.
12. Bedi A, Barber JP, Bedi GC, El-Deiry WS, Sidransky D, Vala MS, Akhtar AJ, Hilton J, Jones RJ. BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: a mechanism of resistance to multiple anticancer agents. Blood 1995; 86: 1148-1158.
13. Gambier N, Chopra R, Strasser A, Metcalf D, Elefanty AG. BCR-ABL activates pathways mediating cytokine independence and protection against apoptosis in murine hematopoietic cells in a dose-dependent manner. Oncogene 1998; 16: 349-357.
14. Maguer-Satta V, Burl S, Liu L, Damen J, Chahine H, Krystal G, Eaves A, Eaves C. BCR-ABL accelerates C2-ceramide-induced apoptosis. Oncogene 1998; 16: 237-248.
15. Engelman A, Rosenberg N. Isolation of temperature-sensitive Abelson virus mutants by site-directed mutagenesis. Proc Natl Acad Sci USA 1987; 84: 8021-8025.
16. Engelman A, Rosenberg N. Temperature-sensitive mutants of Abelson murine leukemia virus deficient in protein tyrosine kinase activity. J Virol 1990; 64: 4242-4251.
17. LaMontagne KRJ, Flint AJ, Franza RB, Pendergast AM, Tonks NK. Protein tyrosine phosphatase 1 B antagonizes signalling by oncoprotein tyrosine kinase p210 bcr-abl in vivo. Mol Cell Biol 1998; 18: 2965-2975.
18. BCR/abl tyrosine kinase on proliferation of a factor-dependent murine myeloid cell line. Oncogene 1994; 9: 149-156.
19. Kabarowski JHS, Allen PB, Wiedemann LM. A temperature sensitive p210 BCR-ABL mutant defines the primary consequences of BCR-ABL tyrosine kinase expression in growth factor dependent cells. EMBO J 1994; 13: 5887-5895.
20. Cristau B, Schafer P, Pierce S. Heat shock enhances antigen processing and accelerates the formation of compact class II αβ dimers. J Immunol 1994; 152: 1546-1556.
21. Duff GW, Durum SK. T cell proliferation induced by interleukin 1 is greatly increased by hyperthermia. Clin Res 1982; 30: 694-699.
22. Kappel M, Diamant M, Hansen MB, Klokker M, Pedersen BK. Effects of in vitro hyperthermia on the proliferative response of blood mononuclear subsets and detection of interleukin 1 and 6, tumor necrosis factor alpha and interferon-gamma. Immunology 1991; 73: 304-308.
23. Huang YH, Haegerstrand A, Frostegard J. Effects of in vitro hyperthermia on proliferative responses and lymphocyte activity. Clin Exp Immunol 1996; 103: 61-66.
24. Palacios R, Steinmetz M. IL-3-dependent mouse clones that express B-220 surface antigen, contain Ig genes in germ-line configuration, and generate B lymphocytes in vivo. Cell 1985; 41: 727-734.
25. McLaughlin J, Chianese E, Witte ON. In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome. Proc Natl Acad Sci USA 1987; 84: 6558-6562.
26. Daley GQ, McLaughlin J, Witte ON, Baltimore D. The CML-specific P210 bcr/abl protein, unlike v-abl, does not transform NIH/3T3 fibroblasts. Science 1987; 237: 532-535.
27. Varticovski L, Daley GQ, Jackson P, Baltimore D, Cantley LC. Activation of phosphatidylinositol 3-kinase in cells expressing abl oncogene variants. Mol Cell Biol 1991; 11: 1107-1113.
28. Varticovski L, Druker B, Morrison D, Cantley LC, Roberts T. The CSF-1 receptor associates with and activates PI 3-kinase. Nature 1989; 342: 699-702.
29. Susa M, Keeler ML, Varticovski L. Platelet-derived growth factor activates membrane-associated phosphatidyinositol 3-kinase and mediates its translocation from the cytosol. J Biol Chem 1992; 267: 22951-22956.
30. Jain SK, Susa-Spring M, Carlesso N, Druker B, Varticovski L. PI 3-kinase activation in BCR/abl-transformed hematopoietic cells does not require interaction of p85 SH2 domains with p210 BCR/abl. Blood 1996; 88: 1542-1550.
31. Sattler M, Salgia R, Shrikhande G, Verma S, Choi IL, Rohrschneider LR, Griffin JD. The phosphatidylinositol polyphosphate 5-phosphatase SHIP and the protein tyrosine phosphatase SHP-2 form a complex in hematopoietic cells which can be regulated by BCR/ABL and growth factors. Oncogene 1997; 15: 2379-2384.
32. cbl in BCR/abl transformed hematopoietic cells mediates enhanced Association with phosphatidylinositol 3-kinase. Oncogene 1997; 14: 2217-2228.
33. Skorski T, Kanakaraj P, Nieborowska-Skorska M, Ratajczak MZ, Wen SC, Zon G, Gewirtz AM, Perussia B, Calabretta B. Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood 1995; 86: 726-736.
34. Klucher KM, Lopez DV, Daley GQ. Secondary mutation maintains the transformed state in BaF3 cells with inducible BCR/ABL expression. Blood 1998; 91: 3927-3934.
35. Fincham VJ, Wyke JA. Localization of temperature-sensitive transformation mutations and back mutations in the Rous sarcoma virus src gene. J Virol 1986; 58: 694-699.
36. Lugo TC, Witte ON. The bcr/abl oncogene transforms Rat-1 cells and cooperates with c-myc. Mol Cell Biol 1989; 9: 1263-1270.
37. Jackson P, Baltimore D. N-terminal mutations activate the leukemogenic potential of the myristoylated form of c-abl. EMBO J 1989; 8: 449-456.
38. Daley GQ, Van Etten RA, Jackson PK, Bernards A, Baltimore D. Nonmyristoylated Abl proteins transform a factor-dependent hematopoietic cell line. Mol Cell Biol 1992; 12: 1864-1871.
39. Skorski T, Kanakaraj P, Skoska MN, Ratajczak MZ, Wen S-C, Zon G, Gewirtz AM, Perussia B, Calabretta B. Phosphatidylinositol 3-kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood 1995; 86: 726-736.
40. Pendergast A-M, Quilliam LA, Cripe LD, Bassing CH, Dai Z, Li N, Batzer A, Rabun KM, Der CJ, Schlessinger J, Gishizky ML. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell 1993; 75: 175-185.
41. Pendergast A, Muller AJ, Havlik MH, Maru Y, Witte ON. BCR sequences essential for transformation by the BCR-ABL oncogene bind to the Abl SH2 regulatory domain in a non-phosphotyrosine-dependent manner. Cell 1991; 66: 161-171.
42. Voncken JW, Kaartinen V, Pattengale PK, Germeraad WTV, Groffen J, Heisterkamp N. BCR/ABL p210 and p190 cause distinct leukemia in transgenic mice. Blood 1995; 86: 4603-4611.
43. Varticovski L, Harrison-Findik D, Keeler ML, Susa M. Role of PI 3-kinase in mitogenesis. Biochim Biophys Acta 1994; 1226: 1-11.
44. Skorski T, Bellacosa A, Nieborowska-Skorska M, Majewski M, Martinez R, Choi JK, Trotta R, Wlodarski P, Perrotti D, Chan TO, Wasik MA, Tsichlis PN, Calabretta B. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. EMBO J 1997; 16: 6151-6161.